Science Explorer Back to mapMap
Discussion
Company · Watertown · United States

EyePoint Pharmaceuticals (United States)

psivida.comROR OpenAlex
Research works
22
▼ 22% vs 2018-21
Citations
228
10.4 per fractional work
Top-10% rate
23.0%
all institutions 10.0%
Open access
30%
world 40%
International
12%
world 18%
EyePoint Pharmaceuticals (United States)

Not ranked overall: EyePoint Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does EyePoint Pharmaceuticals (United States) work in?

In all years, 58% of research at EyePoint Pharmaceuticals (United States) is in Health Sciences, 25% in Life Sciences. Its largest fields are Medicine (58%), Biochemistry, Genetics and Molecular Biology (13%), Engineering (9%). It does 1.9× the world's share of Health Sciences.

Health Sciences: 13 fractional works · 58.0% of its workMedicine: 13 fractional works · 58.0% of its workOphthalmology: 6 fractional works · 25.2% of its workPharmacology: 2 fractional works · 7.6% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 4.7% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 2.5% of its workPathology and Forensic Medicine: 1 fractional works · 2.4% of its workPhysiology: 0 fractional works · 2.3% of its workNephrology: 0 fractional works · 1.9% of its workComplementary and alternative medicine: 0 fractional works · 1.5% of its workGastroenterology: 0 fractional works · 1.5% of its workEpidemiology: 0 fractional works · 1.3% of its workOncology: 0 fractional works · 1.2% of its workRheumatology: 0 fractional works · 1.0% of its workNeurology: 0 fractional works · 0.9% of its workDermatology: 0 fractional works · 0.8% of its workUrology: 0 fractional works · 0.8% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.7% of its workGenetics: 0 fractional works · 0.7% of its workHematology: 0 fractional works · 0.6% of its workObstetrics and Gynecology: 0 fractional works · 0.2% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.2% of its workLife Sciences: 5 fractional works · 24.9% of its workBiochemistry, Genetics and Molecular Biology: 3 fractional works · 13.2% of its workMolecular Biology: 3 fractional works · 12.3% of its workGenetics: 0 fractional works · 0.5% of its workCancer Research: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 5.3% of its workPharmaceutical Science: 1 fractional works · 5.3% of its workNeuroscience: 1 fractional works · 4.6% of its workCellular and Molecular Neuroscience: 0 fractional works · 2.3% of its workNeurology: 0 fractional works · 1.5% of its workCognitive Neuroscience: 0 fractional works · 0.8% of its workAgricultural and Biological Sciences: 0 fractional works · 1.5% of its workPlant Science: 0 fractional works · 1.5% of its workImmunology and Microbiology: 0 fractional works · 0.4% of its workImmunology: 0 fractional works · 0.4% of its workPhysical Sciences: 3 fractional works · 12.5% of its workEngineering: 2 fractional works · 9.1% of its workBiomedical Engineering: 1 fractional works · 4.6% of its workMechanical Engineering: 1 fractional works · 4.6% of its workChemistry: 0 fractional works · 1.5% of its workOrganic Chemistry: 0 fractional works · 1.5% of its workComputer Science: 0 fractional works · 1.5% of its workComputational Theory and Mathematics: 0 fractional works · 1.5% of its workMaterials Science: 0 fractional works · 0.4% of its workPolymers and Plastics: 0 fractional works · 0.4% of its workSocial Sciences: 1 fractional works · 4.6% of its workBusiness, Management and Accounting: 1 fractional works · 4.6% of its workAccounting: 0 fractional works · 2.3% of its workBusiness and International Management: 0 fractional works · 2.3% of its workALL ITS WORKEyePointPharmaceuticals…22fractional works, all years
Life Sciences25%Physical Sciences13%Health Sciences58%Social Sciences5%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 11 fields, with their numbers
    1. Medicine1358.0%
    1. Biochemistry, Genetics and Molecular Biology313.2%
    2. Pharmacology, Toxicology and Pharmaceutics15.3%
    3. Neuroscience14.6%
    4. Agricultural and Biological Sciences01.5%
    5. Immunology and Microbiology00.4%
    1. Engineering29.1%
    2. Chemistry01.5%
    3. Computer Science01.5%
    4. Materials Science00.4%
    1. Business, Management and Accounting14.6%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at EyePoint Pharmaceuticals (United States)?

Ranked on the quality score, Dario A. Paggiarino lead among researchers whose main affiliation is EyePoint Pharmaceuticals (United States).

  1. 1 Dario A. Paggiarino United States · #1,238,960 worldwide 834 citations · 26 works
All ranked researchers at EyePoint Pharmaceuticals (United States)

What are the most cited papers from EyePoint Pharmaceuticals (United States)?

The most cited paper from EyePoint Pharmaceuticals (United States) is "Prevalent Overexpression of Prolyl Isomerase Pin1 in Human Cancers" (Lere Bao, Amy L. Kimzey, Guido Sauter et al., 2004), with 378 citations. Next come "Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: A 3-Year Multicenter, Randomized, Controlled Clinical Trial" (208) and "Sustained Delivery Fluocinolone Acetonide Vitreous Implants" (157).

Most cited papers
#PaperReleasedCitations
1 Prevalent Overexpression of Prolyl Isomerase Pin1 in Human Cancers Lere Bao, Amy L. Kimzey, Guido Sauter et al. · American Journal Of Pathology Open access May 2004 378
2 Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: A 3-Year Multicenter, Randomized, Controlled Clinical Trial P. Andrew Pearson, Timothy L. Comstock, Michael S. Ip et al. · Ophthalmology Aug 2011 208
3 Sustained Delivery Fluocinolone Acetonide Vitreous Implants José Guilherme Cunha-Vaz, Paul Ashton, Raymond Iezzi et al. · Ophthalmology Open access 16 Jun 2014 157
4 Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment Glenn J. Jaffe, Charles Stephen Foster, Carlos Eduardo Pavesio et al. · Ophthalmology Open access 24 Oct 2018 104
5 Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis Glenn J. Jaffe, Phoebe Lin, Robert T. Keenan et al. · Ophthalmology 16 Jul 2016 61
All 37 most cited papers, with filters and sorting

Which keywords describe research at EyePoint Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Alzheimer's Disease, Intravitreal Injection, Macular Degeneration, Oxidative Stress, Glaucoma, Vascular Endothelial Growth Factor, Neurodegenerative Diseases and Pharmacology.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 30 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 30 words, with their numbers
  1. Alzheimer's Disease4▲ 58×4 topics
  2. Epidemiology2▲ 2.9×4 topics
  3. Oxidative Stress2▲ 5.7×4 topics
  4. Intravitreal Injection2▲ 138×2 topics
  5. Macular Degeneration2▲ 75×3 topics
  6. Glaucoma2▲ 53×4 topics
  7. Vascular Endothelial Growth Factor2▲ 84×3 topics
  8. Inflammation2▲ 3.4×4 topics
  9. Neurodegenerative Diseases2▲ 39×2 topics
  10. Pharmacology2▲ 26×2 topics
  11. Acetylcholinesterase2▲ 269×1 topic
  12. Cholinesterase Inhibitors2▲ 269×1 topic
  13. Diabetic Retinopathy2▲ 90×2 topics
  14. Choroidal Thickness2▲ 146×1 topic
  15. Immunosuppressive Therapy2▲ 37×2 topics
  16. Retinal Pigment Epithelium2▲ 146×1 topic
  17. Crystal Structure2▲ 28×2 topics
  18. Neuronal Signaling1▲ 222×1 topic
  19. Nicotinic Acetylcholine Receptors1▲ 222×1 topic
  20. Behçet's Disease1▲ 204×1 topic
  21. Neurodegeneration1▲ 17×2 topics
  22. Optical Coherence Tomography1▲ 49×2 topics
  23. Uveitis1▲ 204×1 topic
  24. Chitosan1▲ 89×1 topic
  25. Nanoparticles1▲ 3.8×1 topic
  26. Acoustic Metamaterials1▲ 119×1 topic
  27. Modular Robots1▲ 132×1 topic
  28. Phononic Crystals1▲ 119×1 topic
  29. Retinal Ganglion Cells1▲ 34×2 topics
  30. Self-Reconfiguration1▲ 132×1 topic

Which research topics does EyePoint Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Retinal Diseases and Treatments, Cancer Cells and Metastasis, Lymphoma Diagnosis and Treatment and Complement system in diseases.

Retinal Diseases and Tre…0Retinal Diseases and Treatments: 0 fractional worksCancer Cells and Metastasis: 0 fractional worksLymphoma Diagnosis and Treatment: 0 fractional worksComplement system in dis…0Complement system in diseases: 0 fractional worksAcute Lymphoblastic Leukemia research: 0 fractional worksRenal Diseases and Glomerulopathies: 0 fractional worksAdvanced Drug Delivery S…0Advanced Drug Delivery Systems: 0 fractional worksOcular Diseases and Behçet’s Syndrome: 0 fractional worksGlaucoma and retinal disorders: 0 fractional worksCancer Immunotherapy and…0Cancer Immunotherapy and Biomarkers: 0 fractional works
OphthalmologyOncologyPathology and Forensic MedicineImmunology3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Retinal Diseases and Treatments Ophthalmology 0 works
  2. 2 Cancer Cells and Metastasis Oncology 0 works
  3. 3 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
  4. 4 Complement system in diseases Immunology 0 works
  5. 5 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 0 works
  6. 6 Renal Diseases and Glomerulopathies Nephrology 0 works
  7. 7 Advanced Drug Delivery Systems Pharmaceutical Science 0 works
  8. 8 Ocular Diseases and Behçet’s Syndrome Ophthalmology 0 works
  9. 9 Glaucoma and retinal disorders Ophthalmology 0 works
  10. 10 Cancer Immunotherapy and Biomarkers Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available30.2%not open69.8%

World: 40% of research is openly available.

with international co-authors11.5%domestic only88.5%

World: 18% is written across borders.

How has EyePoint Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 22% lower than in 2018-2021.

still counting2010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is EyePoint Pharmaceuticals (United States) as a percentage of every work published that year, 0.000014% in 2024.

still counting0.00020%0.00040%EyePoint Pharmaceuticals (United States)0.0000043% in 202519801990200020102020

Fractional works of EyePoint Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Watertown

All research institutions in Watertown

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about EyePoint Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.